Skip to main content
SpringerLink
Log in

Gastric, Pancreas, and Biliary Tract Cancer

  • Chapter
Cancer Chemotherapy by Infusion

  • 87 Accesses

Abstract

Infusion therapy represents a treatment modality exposing tumor cells for longer periods of time. Infusion therapy includes the following modes of administration: (1) short-term continuous i.v. infusion, usually for 5 days; (2) long-term i.v. infusions for 30 days or more; and (3) intra-arterial infusions that may deliver systemic or regional infusions to the tumor bed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Moertel CG. The stomach. In: Hollard JF, Frei E III, eds. Cancer medicine. Philadelphia: Lea & Febiger, 1982; 1767.

    Google Scholar 

  2. Falkson G. Halogenated pyrimidines as radiopotentiators in the treatment of stomach cancer. In: Paoletti R, Vertua R, eds. Progress in biochemical pharmacology-Vol I. Basel and New York: S Karger, 1964.

    Google Scholar 

  3. Falkson G, Sandison AG, Jacobs EL, Fichardt T. Combined telecobalt and 5-fluorouracil therapy in cancer of the stomach. S Afr Med J 1963; 36: 712–17.

    Google Scholar 

  4. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrooke MA. Combined 5-fluorouracil and supervoltage radation therapy of locally unresectable gastrointestinal cancer. Lancet 1969; 2: 865–67.

    Article  PubMed  CAS  Google Scholar 

  5. Kovach JS, Moertel CG, Schutt AJ. A controlled study of combined l,3-bis(2-chloroethyl)-l- nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer 1974; 33: 563.

    Article  PubMed  CAS  Google Scholar 

  6. Moertel CG, Mittelman J A, Bakermeier RF, Engstrom P, Hanely J. Sequential and combination chemotherapy of advanced gastric cancer. Cancer 1976; 38: 678.

    Article  PubMed  CAS  Google Scholar 

  7. Comis RL, Carter SK. Integration of chemotherapy into combined modality treatment of solid tumors. III: Gastric Cancer. Cancer Treat Rev 1974; 1: 221.

    Article  Google Scholar 

  8. Moertel CG. Chemotherapy of gastrointestinal cancer. Clin Gastroenterol 1976; 5:.777.

    PubMed  CAS  Google Scholar 

  9. Moertel CG, Lavin PT. Phase 2–3 chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 1979; 63: 1863.

    PubMed  CAS  Google Scholar 

  10. Gastrointestinal Tumor Study Group. Phase 2–3 chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 1979; 63: 1871.

    Google Scholar 

  11. Kolaric K, Potrebica V, Cervek J. Phase 2 clinical trial of 4′epidoxorubicin in metastatic solid tumors. J Cancer Res Clin Oncol 1983; 106: 148–52.

    Article  PubMed  CAS  Google Scholar 

  12. Robustelli Della Cuna G, Ganzina F, Tramarin R, Pavesi L. Phase 2 evaluation of 4′epidoxorubi- cin in advanced solid tumors. 12th Int Cong Chemother, Florence, Italy; 1982; 75.

    Google Scholar 

  13. Holdener EE, ten Bokkel WH, Hansen HH, et al. Phase 2 trial of 4′-deoxydoxorubicin (4′- deoxyDX) in advanced gastrointestinal cancer. Proc Am Soc Clin Oncol 1984; 3: 139.

    Google Scholar 

  14. Bedikian AY, Stroehlein J, Korinek J, Karlin D, Valdirieso M, Bodey GP. Phase 2 evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with upper gastrointestinal tumors: a preliminary report. Am J Clin Oncol 1983; 6: 473–76.

    Article  PubMed  CAS  Google Scholar 

  15. Leichman L, MacDonald B, Dindogru A, Samson M. Platinum: a clinically active drug in advanced adenocarcinoma of the stomach. Proc Am Assoc Clin Res 1982; 23: 110.

    Google Scholar 

  16. Ajani J, Kantarjian H, Kanojia M, Karlin D. Phase 2 trial of cis-platinum in advanced upper gastrointestinal cancer. Proc Am Soc Clin Oncol 1984; 3: 147.

    Google Scholar 

  17. Gailani S, Holland JF, Falkson G, Leone L, Burningham R, Larsen V. Comparison of treatment of metastatic gastrointestinal cancer with 5-fluorouracil (5-FU) to a combination of 5-FU with cytosine arabinoside. Cancer 1972; 29: 1308–13.

    Article  PubMed  CAS  Google Scholar 

  18. Falkson G, van Eden EB, Sandison AG. A controlled clinical trial of fluorouracil plus imidazole carboxamide dimethyl triazeno plus vincristine plus bis-chloroethyl nitrosourea plus radiotherapy in stomach cancer. Med Pediatr Oncol 1976; 2: 111–17.

    Article  PubMed  CAS  Google Scholar 

  19. MacDonald JS, Wooolley PV, Symthe T, Ueno W, Hoth D, Schein PS. 5-fluorouracil, Adriamy- cin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 1979; 44: 42–47.

    Article  PubMed  CAS  Google Scholar 

  20. MacDonald JS, Schein PS, Woolley PV, et al. 5-fluorouracil, mitomycin-C, and Adriamycin (FAM): a new combination chemotherapy program for advanced gastric carcinoma. Ann Intern Med 1980; 93: 533.

    PubMed  CAS  Google Scholar 

  21. Bitran JD, Desser RK, Kozloff MF, Billings AA, Shapiro CM. Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, Adriamycin, and mitomycin-C (FAM). Cancer Treat Rep 1979; 63: 2049–51.

    PubMed  CAS  Google Scholar 

  22. Haim N, Cohen Y, Honizman J, Robinson E. Treatment of advanced gastric carcinoma with 5- fluorouracil, Adriamycin and mitomycin-C (FAM). Cancer Chemother Pharmacol 1982; 8: 277–80.

    Article  PubMed  CAS  Google Scholar 

  23. Beretta G, Fraschini P, Labianca R, Luponini G. The value of FAM polychemotherapy in advanced gastric carcinoma. Proc ASCO 1982; 1: C–400.

    Google Scholar 

  24. Biran H, Sulkes A. A possible dose response relationship in “FAM” chemotherapy for advanced gastric cancer. Proc Am Soc Clin Oncol 1984; 3: 132.

    Google Scholar 

  25. Haim N, Epelbaum R, Cohen Y, Robinson E. Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin-C (modified FAM). Cancer 1984; 54: 1999–2002.

    Article  PubMed  CAS  Google Scholar 

  26. Gastrointestinal Tumor Study Group. A comparative clinical assessment of combination chemotherapy in the management of advanced gastric cancer. Cancer 1982; 49: 1362–66.

    Article  Google Scholar 

  27. Douglass HO, Lavin PT, Goudsmit A, Klassen DJ. Phase 2–3 evaluation of combinations of methyl-CCNU, mitomycin-C, Adriamycin and 5-fluorouracil in advanced measurable gastric cancer. Proc Am Soc Clin Oncol 1983; 2: 121.

    Google Scholar 

  28. Gastrointestinal Tumor Study Group. Randomized study of combination chemotherapy in unresectable gastric cancer. Cancer 1984; 53: 13–17.

    Article  Google Scholar 

  29. Panettiere FJ, Haas C, McDonald B, et al. Drug combination in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study. J Clin Oncol 1984; 2: 420–24.

    PubMed  CAS  Google Scholar 

  30. Cullinan S, Moertel C, Fleming T, Everson L, Krook J, Schutt A. A randomized comparison of 5- FU alone (F), 5-FU + Adriamycin (FA) and 5-FU + Adriamycin + mitomycin-C (FAM) in gastric and pancreatic cancer. Proc Am Soc Clin Oncol 1984; 3: 137.

    Google Scholar 

  31. Woolley P, Smith F, Estevez R, et al. A phase 2 trial of 5-FU, Adriamycin, and cisplatin (FAP) in advanced gastric cancer. Proc Am Assoc Cancer Res 1981; 22: 455.

    Google Scholar 

  32. Wagner DJM, Burghouts JMM, van Dam FE, et al. A phase 2 trial of 5-fluorouracil, Adriamycin and cisplatin (FAP) in advanced gastric cancer. Proc Am Soc Clin Oncol 1983; 2: 115.

    Google Scholar 

  33. Moertel C, Fleming T, O’Connell M, Schutt A, Rubin J. A phase 2 trial of combined intensive course 5-fluorouracil, Adriamycin and cisplatin in advanced gastric and pancreatic carcinoma. Proc Am Soc Clin Oncol 1984; 3: 137.

    Google Scholar 

  34. Bruckner HW, Stablein DM. Single arm trials of triazinate, cisplatin, and methotrexate combinations in advanced gastric cancer. Proc Am Soc Clin Oncol 1984; 3: 144.

    Google Scholar 

  35. Vogl S, Engstrom PF. Cisplatin, doxorubicin, and 5-fluorouracil in combination for advanced gastric cancer. Cancer Treat Rep 1984; 68: 1273–79.

    PubMed  CAS  Google Scholar 

  36. Haas C, Oishi N, McDonald B, Coltman C, O’Bryan R. Southwest Oncology Group phase 2–3 gastric cancer study: 5-fluorouracil, Adriamycin and mitomycin-C + vincristine (FAM versus V-FAM) compared to chlorozotocin (CZT), m-AMSA, and dihydroxyanthracenedione (DHAD) with unimpressive differences. Clinical trials: gastrointestinal tract. Proc Am Soc Clin Oncol 1983; 2: 122.

    Google Scholar 

  37. Beretta G, Fraschini P, Ravaioli A, Amadori D, Luporini G. FA/FAMB polychemotherapy for advanced carcinoma of the stomach (ACS): a randomized study. Clinical trials: gastrointestinal tract. Proc Am Soc Clin Oncol 1983; 2: 131.

    Google Scholar 

  38. Carter SK, Comis RL. Adenocarcinoma of the pancreas, prognostic variables, and criteria of response. In: Staquet MJ, ed. Cancer therapy: prognostic factors and criteria of response. New York: Raven Press, 1975; 237.

    Google Scholar 

  39. Douglass HO Jr, Lavin PT, Moertel CG. Nitrosoureas: useful agents for treatment of advanced gastrointestinal cancer. Cancer Treat Rep 1976; 60: 769.

    PubMed  Google Scholar 

  40. Broder LE, Carter SK. Streptozotocin: clinical brochure. Bethesda: Thereapy Evaluation Program, National Cancer Institute, 1971.

    Google Scholar 

  41. Dupriest RW, Hintington M, Massey WH, Wiess AJ, Wilson WL, Fletcher WS. Streptozotocin therapy in 22 cancer patients. Cancer 1974; 35: 358–67.

    Article  Google Scholar 

  42. Stolinsky DC, Sadoff L, Braunwald J, Bateman JR. Streptozotocin in the treatment of cancer: phase 2 study. Cancer 1972; 30: 61–67.

    Article  Google Scholar 

  43. Schein PS, Lavin PT, Moertel CG, et al. Randomized phase 2 clinical trial of Adriamycin, methotrexate and actinomycin-D, in advanced measurable pancreatic carcinoma. A Gastrointestinal Tumor Study Group report. Cancer 1978; 42: 19–22.

    Article  PubMed  CAS  Google Scholar 

  44. Nicoletto O, Vinante O, Cartei G. Clinical activity of 4′-epi-doxorubicin in advanced pancreatic adenocarcinoma (abstr). EORTC Symp on treatment of advanced gastrointestinal cancer. Padova 23, 1983.

    Google Scholar 

  45. Hochster H, Green M, Speyer J, Blum R, Wernz J, Muggia F. Activity of 4′-epidoxorubicin (EPIDX) in hepatoma (HEP) and pancreatic cancer (PANC). Proc Am Soc Clin Oncol 1984; 3: 147.

    Google Scholar 

  46. Horton J, Gelbert RD, Engstrom P, et al. Trials of single-agent and combiantion chemotherapy for advanced cancer of the pancreas. Cancer Treat Rep 1981; 65: 65–68.

    PubMed  CAS  Google Scholar 

  47. Loehrer PJ, Williams SD, Einhorn LH, Estes NC. A phase 1–2 trial of ifosfamide (IFOS) and N- acetylcysteine (NAC) in advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 1984; 3: 149.

    Google Scholar 

  48. Lokich J, Chawla PL, Brooks J, Frei E III. Chemotherapy in pancreatic carcinoma: 5-fluorouracil (5-FU) and 1,3 Bis-(2 chlorethyl)-l-nitrosourea (BCNU). Ann Surg 1974; 179(4): 450–53.

    Article  PubMed  CAS  Google Scholar 

  49. Wiggans G, Woolley PV, MacDonald JS, Smythe T, Ueno W, Schein PS. Phase 2 trial of strepto- zotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer 1978; 41: 387–95.

    Article  PubMed  CAS  Google Scholar 

  50. Bukoski RM, Abderhalten RT, Hewlett JS. Phase 2 trial of streptozotocin, mitomycin-C and 5- fluorouracil in adenocarcinoma of the pancreas. Cancer Clin Trials 1980; 3: 321.

    Google Scholar 

  51. Bitran JD, Desser RK, Kozloff MF, Billings AA, Shapiro CM. Treatment of metastatic pancreatic and gastric adenocarcinoma with 5-fluorouracil, Adriamycin and mitomycin-C (FAM). Cancer Treat Rep 1979; 63: 2049–51.

    PubMed  CAS  Google Scholar 

  52. Smith FP, Hoth DF, Levin BL. 5-fluorouracil, Adriamycin and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 1980; 46: 2014.

    Article  PubMed  CAS  Google Scholar 

  53. Sternberg CN, Magill GB, Sordillo PP, Cheng E. Preliminary trial of MIFA III (mitomycin-C, 5- fluorouracil and Adriamycin) in adenocarcinoma of the pancreas. Clinical trials: gastrointestinal tract. Proc Am Soc Clin Oncol 1982; 1: 99.

    Google Scholar 

  54. Smith FP, Stablein DM, Schein PS. Phase 2 combination chemotherapy trials in advanced measurable pancratic cancer. Proc Am Soc Clin Oncol 1984; 3: 151.

    Google Scholar 

  55. Oster MW, Theologides A, Cooper MR, et al. Fluorouracil (F) + Adriamycin (A) + mitomycin (M) (FAM) versus fluorouracil (F) + streptozotocin (S) + mitomycin (M) (FSM) in advanced pancreatic cancer. Proc Am Soc Clin Oncol 1982; 1: 90.

    Google Scholar 

  56. Bukowski RM, Schacter LP, Groppe CW. Phase 2 trial of 5-fluorouracil, Adriamycin, mitomycin- C and streptozotocin (FAM-S) in pancreatic carcinoma. Cancer 1982; 50: 197.

    Article  PubMed  CAS  Google Scholar 

  57. Smith FP, Priego V, Lokey L, et al. Phase 2 evaluation of hexamethylmelamine + FAM (HEXA - FAM) in advanced measurable pancreatic cancer (PC). Proc Am Soc Clin Oncol 1983; 2: 126.

    CAS  Google Scholar 

  58. Smith FP, Rustgi VK, Schertz G, Woolley PV, Schein PS. Phase 2 study of 5-FU, doxorubicin and mitomycin (FAM) and chlorozotocin in advanced measurable pancreatic cancer. Cancer Treat Rep 1982; 66(12): 2095–96.

    PubMed  CAS  Google Scholar 

  59. Gisselbrecht C, Smith FP, Woolley PV, et al. Phase 2 trial of FAP (5-fluorouracil, Adriamycin and cisdiammin dichloroplatinum) chemotherapy for advanced measurable pancreatic cancer (PC) and adenocarcinoma of unknown origin (AUO). Proc Am Soc Clin Oncol 1981; 22: 454.

    Google Scholar 

  60. Falkson G. The management of tumours of the liver and biliary tract. In: Carter SK, Gladstein E, Livingston RB, eds. Principles of cancer treatment. New York: McGraw Hill, 1982; 426–433.

    Google Scholar 

  61. Haskell CM. Cancer of the liver. In: Haskell CM, ed. Cancer treatment. Philadelphia: WB Saunders, 1980; 319–570.

    Google Scholar 

  62. Cambareri RJ, Smith FP, Kales A, Warren R, Woolley PV, Schein PS. 5-fluorouracil, Adriamycin and mitomycin-C in cholangiocarcinoma. Proc Am Soc Clin Oncol 1980; 21: 419.

    Google Scholar 

  63. Harvey JH, Smith FP, Schein PS. 5-fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984; 2(11).

    Google Scholar 

  64. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984; 54: 965–69.

    Article  PubMed  CAS  Google Scholar 

  65. Sullivan RD, Young CW, Miller E, Gladstein E, Clarkson B, Burchenal JH. The clinical effects of the continuous administration of fluorinated pyrimidines (5-fluorouracil and 5-fluoro-2′-deoxyuridine). Cancer Treat Res 1960; 8: 77–83.

    CAS  Google Scholar 

  66. Reitemeier RJ, Moertel CG. Comparison of rapid and slow intravenous administration of 5- fluorouracil in treating patients with advanced carcinoma of the large intestine. Cancer Chemother Rep 1962; 25: 87–89.

    PubMed  CAS  Google Scholar 

  67. Seifert P, Baker LH, Reed ML, Vaitkevicius VK. Comparison of continuously infused 5- fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123–28.

    Article  PubMed  CAS  Google Scholar 

  68. Grillo-Lopez AZ, Velez-Garcia E, Elliott A. Survival of patients with advanced gastrointestinal cancer treated with 5-fluorouracil (5-FU) Proc Am Soc Clin Oncol, 1977.

    Google Scholar 

  69. Nixon DW, Vogler WR, Jacobs J, Heffner LT, Winton EF, Garrett PR. Phase 1 study of 5-FU- methyl CCNU - methotrexate with leucovorin in advanced adenocarcinoma. Proc Am Cancer Res 1978; 19: 326.

    Google Scholar 

  70. Hartman HA Jr, Kessinger A, Lemon HM, Foley JF. Five-day continuous infusion of 5- fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma. J Surg Oncol 1979; 11: 227–38.

    Article  PubMed  Google Scholar 

  71. Krauss S, Sonoda T, Solomon A. Treatment of advanced gastrointestinal cancer with 5- fluorouracil and mitomycin-C. Cancer 1979; 43: 1598–1603.

    Article  PubMed  CAS  Google Scholar 

  72. Lokich JJ. Protracted ambulatory venous infusion of chemotherapeutic agents (meeting). Strategies for clinical cancer 22–24, 1980.

    Google Scholar 

  73. Lokich JJ, Bothe A, Fine N, et al. Phase 1 study of protracted venous infusion of 5-fluorouracil. Cancer 1981; 48: 2565–68.

    Article  PubMed  CAS  Google Scholar 

  74. Lokich JJ, Philips D, Perri J, et al. Cancer chemotherapy via ambulatory infusion pump. Am J Clin Oncol (CCT) 1983; 6: 355–63.

    Article  CAS  Google Scholar 

  75. Vaughn CB, Brady P, Chinn BJ, Daversa GC, Parzuchowski JS. Combination chemotherapy in advanced gastrointestinal malignancy. Oncology 1980; 37: 57–61.

    Article  PubMed  CAS  Google Scholar 

  76. Bruckner HW, Storch JA, Brown JC, Goldberg J, Chamberlin K. Phase 2 trial of combination chemotherapy for pancreatic cancer with 5-fluorouracil, mitomycin-C and hexamethylmelamine. Oncology 1983; 40: 165–69.

    Article  PubMed  CAS  Google Scholar 

  77. Cazap E. Phase 2 study of bleomycin (BL) by 5-day continuous intravenous infusion (5-CII) in advanced adenocarcinoma (AA). Proc Am Soc Clin Oncol 1984; 3: 45.

    Google Scholar 

  78. Bukowski RM, Vaughn CB, Hampton J, Stuckey WJ. Anguidine in gastrointestinal malignancies: SWOG phase 2 study (meeting abstr). Proc Am Assoc Cancer Res 1980; 21: 352.

    Google Scholar 

  79. Falkson G, Lombaard CM, McDonald TPS. the Treatment of advanced cancer with intra-arterial triethyleneglycol diglycidyl ether. S Afr Cancer Bull 1964; 8: 3–17.

    Google Scholar 

  80. Geddes EW, Falkson G. Malignant hepatoma in the Bantu. Cancer 1970; 25: 1271–78.

    Article  PubMed  CAS  Google Scholar 

  81. Freckman HA. Arterial infusion chemotherapy. In: Badellino F, ed. 4th int symp on locoregional treatment of tumors-III. Saint Vincent: Pan Med 17: 277–79.

    Google Scholar 

  82. Davis HL Jr, Ramirez G, Ansfield FJ. Adenocarcinomas of stomach, pancreas, liver and biliary tracts (survival of 328 patients treated with fluoropyrimidine therapy). Cancer 1974; 33: 193–97.

    Article  PubMed  Google Scholar 

  83. Yoshikawa, K. Ten years experience with intra-aortic infusion chemotherapy for gastrointestinal malignant tumors. Proc in Oncol 1981; 11(2): 351.

    Google Scholar 

  84. Theodor A, Livingston RB, Bukowski RM, Weick JK, Hewlett JS. Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Am J Clin Oncol (CCT) 1982; 5: 555–58.

    Google Scholar 

  85. Marlow Lord Smith, Gazet JC. Intra-arterial chemotherapy for patients with inoperable carcinoma of the pancreas. Ann R Coll Surg Eng 1980; 62: 208–12.

    Google Scholar 

  86. Vogelzang NJ. Continuous infusion chemotherapy: a critical review. J Clin Oncol 1984; 2: 1289–1304.

    PubMed  CAS  Google Scholar 

  87. Lokich JJ, Becker B. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer 1983; 52: 1586–89.

    Article  PubMed  CAS  Google Scholar 

  88. Clouse ME, Ahmed R, Ryan RB, et al. Complications of long-term transbrachial hepatic arterial infusion chemotherapy. Am J Roentgenol 1977; 129: 799–803.

    CAS  Google Scholar 

  89. Anderson JR, Cain KC, Gelber RD, Gelman RS. Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials. Cancer Treat Symp (in press).

    Google Scholar 

Download references

Authors
  1. Geoffrey Falkson M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Baruch Klein M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Precept Press, Inc.

About this chapter

Cite this chapter

Falkson, G., Klein, B. (1987). Gastric, Pancreas, and Biliary Tract Cancer. In: Cancer Chemotherapy by Infusion. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-3193-0_23

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-3193-0_23

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-7932-7

  • Online ISBN: 978-94-009-3193-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation